# LOTS (NCT07153055)

> Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: lurbinectedin plus osimertinib
- Indication: transformed small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07153055
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Misty Shields
- Conditions: Small Cell Lung Cancer ( SCLC ); Transformed Small Cell Lung Cancer
- Interventions: Lurbinectedin; Osimertinib
- Enrollment: 16
- Primary outcome: Grade 3 or dose-limiting toxicities

## Indexed commentary on LOTS so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 6 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=lots-nct07153055
